Compare Adaptive Biotechnologies Corp (ADPT) vs Avantis International Small Cap Value ETF (AVDV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Avantis International Small Cap Value ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Avantis International Small Cap Value ETF trades at $102.75. Which is the better fit depends on your goals.
| ADPT | AVDV | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $110.40 |
52-Week Low | $10.24 | $80.02 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AVDV trades at $105.77, up 1.29% today, with a bullish technical signal from moving averages. The ETF focuses on international small-cap value stocks, delivering strong performance with 35% gains highlighted in recent coverage. Dividend payments provide additional investor returns, with the next $1.39 distribution scheduled for June 2026.
Outlook remains positive given international small-cap value momentum, though cyclical sector exposure and reliance on regional factors present risks. Structural alpha concerns noted by analysts suggest monitoring performance drivers beyond broad market trends for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →
